Viking Therapeutics (VKTX) Operating Leases (2019 - 2025)
Historic Operating Leases for Viking Therapeutics (VKTX) over the last 6 years, with Q3 2025 value amounting to $318000.0.
- Viking Therapeutics' Operating Leases fell 5788.08% to $318000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $318000.0, marking a year-over-year decrease of 5788.08%. This contributed to the annual value of $630000.0 for FY2024, which is 3269.23% down from last year.
- According to the latest figures from Q3 2025, Viking Therapeutics' Operating Leases is $318000.0, which was down 5788.08% from $410000.0 recorded in Q2 2025.
- In the past 5 years, Viking Therapeutics' Operating Leases ranged from a high of $1.5 million in Q1 2022 and a low of $318000.0 during Q3 2025
- For the 4-year period, Viking Therapeutics' Operating Leases averaged around $931266.7, with its median value being $936000.0 (2023).
- As far as peak fluctuations go, Viking Therapeutics' Operating Leases crashed by 2073.83% in 2023, and later tumbled by 5788.08% in 2025.
- Quarter analysis of 4 years shows Viking Therapeutics' Operating Leases stood at $1.3 million in 2022, then decreased by 25.71% to $936000.0 in 2023, then crashed by 32.69% to $630000.0 in 2024, then plummeted by 49.52% to $318000.0 in 2025.
- Its last three reported values are $318000.0 in Q3 2025, $410000.0 for Q2 2025, and $502000.0 during Q1 2025.